Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
Healthcare
$1.03 +6.12%
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
52W Low $0.27High $1.83
Volume 1.85M
Average 5.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$60.29M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$6.03M
FY 2025 · Annual
-53.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.1M | 7.4M | 8.01M | 8.83M | 6.25M |
| Change in Working Capital | 2.28M | 2.54M | (5.89M) | 2.53M | (8.21M) |
| Accounts Receivables | 0 | (6.93M) | 5.58M | 1.35M | 0 |
| Inventory | 0 | 6.93M | 0 | 0 | 0 |
| Accounts Payables | 1.01M | (883K) | (4.34M) | 3.46M | (7.5M) |
| Other Working Capital | 1.27M | 3.42M | (7.14M) | (2.28M) | (707K) |
| Other Non-Cash Items | 519K | 2.17M | 878K | 1.16M | 856K |
| Operating Cash Flow | (42.88M) | (40.6M) | (32.61M) | (56.19M) | (60.29M) |
| Capital Expenditures | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Debt Repayment | 0 | 0 | 40M | (10M) | 0 |
| Common Stock Issued | 111.6M | 15.74M | 18.33M | 23.58M | 6.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | 166K | 100K | (496K) | 0 |
| Financing Cash Flow | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 66.05M | (28.3M) | 25.05M | (43.36M) | (54.26M) |
| Free Cash Flow | (43.37M) | (44.21M) | (33.38M) | (56.44M) | (60.29M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$60.8M
+ D&A$1.6M
+ Stock-Based Comp$6.2M
+ Deferred Tax$0
- Working Capital-$8.2M
+ Other Non-Cash$856.0K
= Operating Cash Flow-$60.3M
- Capex$0
= Free Cash Flow-$60.3M
Analysis
FY2025 free cash flow is -$60.3M. FCF conversion is 99.1% of net income. Operating cash flow was -$60.3M, with capex of $0. The largest bridge item is Working Capital at -$8.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 16, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| EFFECT | EFFECT filing | Nov 12, 2026 | |
| 424B3 | 424B3 filing | Nov 12, 2026 | |
| S-4/A | S-4/A filing | Nov 10, 2026 |
Does HOWL generate free cash flow?
Werewolf Therapeutics, Inc. (HOWL) generated -$60.29M of free cash flow in fiscal 2025.
How much operating cash flow does HOWL produce?
Operating cash flow was -$60.29M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.